On Nov. 18, 2020, BioVersys announced a milestone by entering clinical development with the start of Phase 1 testing of BV100 in healthy volunteers.

BioVersys announced that the first healthy volunteers received BV100 in a Phase 1 clinical trial designed to evaluate the safety, tolerability, and pharmacokinetics of BV100 in healthy human volunteers through Single Ascending Dose and Multiple Ascending Dose studies.